Wall St. also had this article on Nov 20th. funny it was on the MGNX news board but not here. This article is kind of weak but it does mention Cemp.
Cempra Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. It announced this week that it has received authorization under its existing contract for the next phase of its contract with the Biomedical Advanced Research and Development Authority (BARDA) that will provide funding of $16.0 million for two clinical studies of solithromycin. The Stifel team views the initial read on the Solitaire-Oral study as indicating there may be label expansion possibilities for solithromycin.
The Stifel price target is $22, and the consensus target is $19.50. The stock closed Wednesday at $13.22. Trading to the Stifel target would be a 63% gain.
Look at all those options….lol These guys sure pay themselves very well for making no money for shareholders. All lawyers that do class action, please write me.
Shhhhhhh. I want even more shares. I think most stocks are at fair value now in the market and IBB is up nicely yet CEMP is still extremely cheap. ACAD( my other bio) has a huge market cap do to a billion dollar drug most likely approved yet CEMP has a MULTI- billion drug most likely and a small 400 mil market cap. CEMP may be revisited in December by funds and bid up as it is the last hidden gem that is super cheap. Again, thanks for the shares this week to all that sold to me.
CEMP is worth more $$ on a buy out than TTPH. TTPH has a nice powerful drug and I was shocked to hear that the oral is tolerable. I still think a body friendly Macrolide will be prescribed in the community setting for simple Gonorrhea before they would consider TTPH. Trial Results are in the first quarter. I would bet on end of January.I would be real surprised if Cemp isn't bought for $40 or more next year. They have money to last to 2016. The secondary may never get issued if Cemp is bought out in 2015. I say there is a 50/50 chance they do it when Cemp pops to $24 on the news. Its a multi billion drug. The secondary is chump change to hire a sells force. The drug will sell its self. They probably shouldn't sell the company. I think $60 pps is possible in 3 years. Cheers
I had Celgene and VRTX and other great bio's back in the day when they were cheap. Right before trial results they all sold off. It Scared a lot of investors out. It might happen here to. I wouldn't be surprised if I were able to get more of Cemp at 11:50. But I doubt it. Anti biotics almost always replicate phase 11 and the funds know it.
Z-Pak fills 51 million of prescriptions yearly world wide in 2013. It has been the best selling anti biotic/macrolide in history. Cemp will replace Z-Pac but also be used in mono therapy for CAPD in the community setting and IV in hospital. Gonnerea in community string. No pills available at the moment. COPD- I bet it helps. NASH- I bet it helps. Children? Yes, first adolescent ant-biotic in 25 yrs. You can do the math. Multi billion drug. Im buying a villa from Cemp. You are all invited.
I don't see panic at all. The volume would be huge but isn't. I see a huge buying opp. Im still confused why they would halt enrollment for this type of patient,but whatever, I bought more. Thanks for the Christmas present.
I thought the extreme short position was do to the advertising #$%$. I always thought the drug is better and couldn't understand the high short position. What a coincidence the shorts can now cover with a nice profit. Bio investing is not for the faint of heart
Nice buying op.
um…count me in on that group. Sold DRTX at 17.50 with nice gain. Im not leaving money on the table here though. We are talking first line defense in the community setting on many fronts. Im one of CEMP's largest private share holders and will be holding a long time.
Soli may well fetch 100 share. Its not a pipe dream at all. Azith is not prescribed for CABP and Soli will be. Soli will be prescribed for common gonorrhea in the community settling as well. The company dosnt want to over prescribe for typical light infections.
They are toast
20,000? Is that a fact? Doxil treats failed patients and adds appx 2-4 months to life? I didn't know they got that much $ for 2 months. What has been Doxil main competition over the yrs? Any off label drug that is giving and extra 2-4 months or even more?
I think its because this isn't a cancer cure or a first line prescribed drug. It will make what……400,000 yr maybe? It just isn't a glamour drug like ISiS is developing or Celg etc. Im watching,buying a few shares here because of being undervalued at $2.75. When/if other companies partner with CYTR's binder and they have their NDA, CYTR will trade much higher. cheers.